Andre Esteva, Co-Founder and CEO of ArteraAI, shared on LinkedIn:
“ArteraAI’s tests serves patients across all major subgroups of prostate cancer.
Just published in the latest version of the National Comprehensive Cancer Network (NCCN) guidelines – the global gold standard for oncology – we have additionally been recommended for use in post-radical prostatectomy patients.
These are patients in the prevalence population who’ve undergone surgery and still need additional treatment.
Our team has published close to 85 pieces of top-tier evidence over the last 5 years to justify all the ways in which clinicians can use our tools.”
You can also read: TRACE-I: Long-Term Outcomes of PSMA-Guided Salvage Surgery in Recurrent Prostate Cancer
